Hair Loss, considered.
The hair-loss industry sells hope in a hundred bottles; the medicine fits on an index card. Two drugs have substantiated evidence. Everything else is adjunct, gray zone, or marketing.
What's actually happening.
Androgenetic alopecia — pattern hair loss — is driven by follicular sensitivity to DHT, a testosterone derivative. Follicles progressively miniaturize: each growth cycle produces a finer, shorter hair until the follicle stops producing visible hair at all. The process is gradual, genetic, and affects most men and a large share of women over a lifetime.
The clinical implication is unglamorous but central: miniaturized follicles can often be revived; dead ones cannot. Treatment preserves and partially restores what's still active, which is why the same medication produces better outcomes in a 28-year-old than a 55-year-old. If loss is sudden, patchy, or accompanied by shedding in clumps, that's not pattern loss — telogen effluvium, alopecia areata, thyroid and iron issues all present differently and need a clinician's diagnosis, not a subscription.
The two with real evidence.
Finasteride (oral, 1mg) is FDA-approved for male pattern hair loss. It lowers scalp DHT and, in the pivotal trials, stopped further loss in the large majority of men, with modest regrowth in a meaningful share. The honest counterweight: a small minority report sexual side effects (reduced libido, erectile changes) and mood effects; most resolve on discontinuation, while a debated set of persistent cases is reported. This is a medication to discuss with a prescriber, not to source anonymously. Women who are or may become pregnant must not take or handle broken tablets — it can affect a male fetus.
Minoxidil is FDA-approved topically for men and women; low-dose oral minoxidil is an increasingly common off-label prescription with growing supportive literature. It works downstream of hormones — extending the growth phase — so it pairs naturally with finasteride rather than replacing it. Expect a temporary shedding phase in the first weeks (a sign of cycling, not failure), visible judgment at six to twelve months, and benefits that persist only while you continue.
The gray zone, honestly labeled.
Low-level laser devices have early evidence that suggests modest benefit for some users — 'may help' is the strongest claim the data supports, and the device industry routinely exceeds it. Ketoconazole shampoo is a reasonable, cheap adjunct. Saw palmetto and most supplements have weak or no human outcome data. Peptide serums and exosome treatments are, for now, plausibility plus a price tag — no one can yet show you robust trial results, and we don't list claims that can't be substantiated.
None of these belong ahead of the two evidenced medications. If a provider or product leads with the gray zone while skipping finasteride and minoxidil, you're being marketed to, not treated.
Beyond the pharmacy — and how to get treated.
PRP injections have growing but mixed evidence as an adjunct: a series of sessions, then maintenance, with results that vary meaningfully between studies and clinics. An FUE transplant is the definitive option for suitable candidates — but transplanted hair sits within native hair that keeps miniaturizing, which is why surgeons worth their fee insist on medical stabilization first. The sequencing is the strategy: stabilize with medication, reassess at a year, then decide whether procedures earn their cost.
Practically, straightforward male pattern loss is well-served by telehealth prescribing — the medications are generic and inexpensive, and follow-up is simple. Diagnostic uncertainty, female-pattern or patchy loss, and scarring presentations belong with a dermatologist in person. Either way, the consultation questions in our journal apply unchanged: what would make you advise against treating, and what does this cost over a year, not a month.
Common questions.
How early should I start?
Earlier than feels necessary. Treatment preserves existing follicles far better than it revives lost ones, so the best outcomes belong to people who start while their loss still looks minor. If you can see recession or thinning in photos, the decision window is open now.
Are finasteride's side effects permanent?
For most men who experience side effects, they resolve after stopping the medication. A persistent post-discontinuation syndrome has been reported and remains debated in the literature. The responsible approach: know the profile going in, get the prescription from a clinician who will actually follow up, and report changes early rather than pushing through.
Can women use these medications?
Topical minoxidil is FDA-approved for women and is the first-line option. Finasteride is not used in women who are or may become pregnant — fetal risk is the hard line — though post-menopausal use is sometimes prescribed off-label by dermatologists. Female hair loss has a broader differential (iron, thyroid, hormonal shifts), which is why it warrants an in-person workup.
When will I see results?
Hair cycles are slow. Three to six months is the minimum before judging anything; twelve months is the honest evaluation point. Photos in consistent lighting beat memory — take them at the start.
Do I have to stay on it forever?
Benefits persist only while treatment continues. Stop, and the underlying process resumes within months. Treat the decision like starting a long-term medication, because it is one — and budget accordingly (generics keep it modest).
Should I just do PRP or a transplant instead?
Procedures work best on a medically stabilized scalp, not instead of one. PRP is an adjunct with mixed evidence; a transplant relocates follicles but doesn't stop ongoing loss around them. Most good surgeons will tell you to take the index-card medicine first — that's a sign you've found a careful one.